To date, the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …

In less than one year since the outbreak of the COVID-19 pandemic, two mRNA-based
vaccines, BNT162b2 and mRNA-1273, were granted the first historic authorization for …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus
disease 2019 (COVID-19), emerged in China in December 2019 and quickly spread around …

The recent success of mRNA vaccines in SARS-CoV-2 clinical trials is in part due to the
development of lipid nanoparticle delivery systems that not only efficiently express the …

The development of effective vaccines to combat infectious diseases is a complex multi-year
and multi-stakeholder process. To accelerate the development of vaccines for coronavirus …

Since the first successful application of messenger ribonucleic acid (mRNA) as a vaccine
agent in a preclinical study nearly 30 years ago, numerous advances have been made in …

In December 2019, a new and highly pathogenic coronavirus emerged—coronavirus
disease 2019 (COVID-19), a disease caused by severe acute respiratory syndrome …

Since the outbreak of coronavirus disease 2019 (Covid‐19) in December 2019, caused by
the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the number of …

There is growing need for a safe, efficient, specific and non-pathogenic means for delivery of
gene therapy materials. Nanomaterials for nucleic acid delivery offer an unprecedented …

Recent medical advances have exploited the ability to address a given disease at the
underlying level of transcription and translation. These treatment paradigms utilize nucleic …